BioCentury
ARTICLE | Clinical News

Cavatak: Preliminary Ph Ib data

November 10, 2016 11:19 PM UTC

Preliminary data from 8 evaluable patients with ≥1 injectable lesion in the open-label, U.S. Phase Ib CAPRA trial showed that intratumoral Cavatak plus Keytruda pembrolizumab was well tolerated with n...